Angiotensin IV analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-13. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
In Greenland, local markets known as brætter sell food from wild animals, including seal meat, whale meat, reindeer meat, and polar bear meat. Brætter do not sell live animals, but most meat sold in brætter is fresh and recently butchered. While larger towns have purpose-built facilities, the brætter in smaller towns and village settlements sell seafood in open-air stands without running water or electricity. Only fresh meat was allowed to be sold in Nuuk at Kalaaliaraq Market, the largest fresh food market in Greenland, until 2018 when the government of Greenland began permitting the sale of dried and salted meat at Kalaaliaraq. Trichinosis is a common problem in Greenland due to the consumption of wild polar bear meat. In 2016, several people were infected with Trichinella roundworms from eating polar bear meat from a local brætter even though the meat had initially passed inspections. As of 2017, Trichinella inspections for seal and polar bear meat sold at brætter is not mandatory.
The introduction of the F gene of SeV in the form of a plasmid into the tumor tissue in mice by electroporation showed that the expression of the F gene increases the T cell infiltration of the tumor with CD4+ and CD8+ cells and inhibits tumor growth. It was also shown in other similar experiments that cancer cells themselves, transfected with plasmids that encode viral membrane glycoproteins with fusion function, cause the collective death of neighboring cells forming syncytium with them. Recruitment of bystander cells into the syncytium leads to significant regression of the tumor.
=== By mouth === If taken by mouth it is toxic. Side effects may include nausea, vomiting, and shortness of breath may occur. If a sufficiently large amount (about 10 grams) is eaten death may occur. Concentrated solutions when drunk have resulted in Acute Respiratory Distress Syndrome or swelling of the airway. Recommended measures for those who have ingested potassium permanganate include gastroscopy. Activated charcoal or medications to cause vomiting are not recommended. While medications like ranitidine and N-acetylcysteine may be used in toxicity, evidence for this use is poor.
Sources: en.wikipedia.org
HCO2CH3 + NH3 → HC(O)NH2 + CH3OH 2 HC(O)NH2 + 2H2O + H2SO4 → 2HCO2H + (NH4)2SO4 A disadvantage of this approach is the need to dispose of the ammonium sulfate byproduct. This problem has led some manufacturers to develop energy-efficient methods of separating formic acid from the excess water used in direct hydrolysis. In one of these processes, used by BASF, the formic acid is removed from the water by liquid-liquid extraction with an organic base.
Despite a rally on January 15 on news of lower unemployment insurance claims, the Dow Jones, the Nasdaq, and the S&P 500 closed just below their opening bell valuations on January 16 and finished the week at a loss upon news that Trump suggested that the most likely candidate to replace Powell as Federal Reserve Chair had changed and threats by Trump to impose import tariffs on countries that oppose the United States acquiring Greenland. Over the same two days, the dollar strengthened, gold prices fell, and yields on 2-year and 10-year Treasury notes rose. As indicated by the weakening of the U.S. dollar on its exchange rates, the precious metals price increases, and the rising yields and steepening yield curve on Treasury notes in the bond market over the week following Powell's announcement, market analysts have observed that the investigation and potential loss of the Federal Reserve's independence (along with the geopolitical risks) indicates higher long-term inflation expectations by investors and has reinforced interest for greater global diversification of investment holdings and away from U.S. assets. JPMorgan Chase CEO Jamie Dimon and BNY CEO Robin Vince both criticized the investigation, arguing that undermining the Federal Reserve's independence would raise inflation expectations, increase interest rates in the long-term, and undermine the functioning of the bond market.
== Composition == OFM comprises more than 24 collagens (most notably types I and III), but also contains many growth factors, polysaccharides and proteoglycans that naturally exist as part of the extracellular matrix and play important roles in wound healing and soft tissue repair. The composition includes more than 150 different proteins, including elastin, fibronectin, glycosaminoglycans, basement membrane components, and various growth factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet derived growth factor (PDGF). OFM has been shown to recruit mesenchymal stem cells, stimulate cell proliferation, angiogenesis and vascularogenesis, and modulate matrix metalloproteinase and neutrophil elastase. The porous structure of OFM has been characterized by differential scanning calorimetry (DSC), scanning electron microscopy (SEM), atomic force microscopy (AFM), histology, Sirius Red staining, small-angle x-ray scattering (SAXS), and micro computerized topography (MicroCT). OFM has been shown to contain residual vascular channels that facilitate blood vessel formation through angioconduction.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.